Last 7 days
11.5%
Last 30 days
6.3%
Last 90 days
16.2%
Trailing 12 Months
0.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
A | 39.3B | 6.8B | -5.76% | -1.62% | 31.3 | 5.73 | 8.37% | 3.64% |
ILMN | 34.4B | 4.6B | 10.80% | -36.26% | -7.81 | 7.51 | 1.28% | -677.95% |
MTD | 32.8B | 3.9B | 3.74% | 6.71% | 37.59 | 8.37 | 5.43% | 13.46% |
WAT | 17.9B | 3.0B | -3.60% | -7.13% | 25.24 | 6.01 | 6.68% | 2.15% |
PKI | 16.2B | 3.3B | 2.29% | -27.60% | 28.4 | 4.88 | -34.64% | -39.65% |
MID-CAP | ||||||||
SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | 6.27% | 0.87% | -6.41 | 15.69 | -1.69% | -73.40% |
ADPT | 1.1B | 185.3M | 4.81% | -31.55% | -5.67 | 6.12 | 20.06% | 3.42% |
QTRX | 401.5M | 105.5M | -5.95% | -61.12% | -4.15 | 3.8 | -4.55% | -67.63% |
NSTG | 401.3M | 127.3M | -3.95% | -71.99% | -2.52 | 3.15 | -12.28% | -38.43% |
BNGO | 323.9M | 27.8M | -13.39% | -53.59% | -2.44 | 11.65 | 54.62% | -83.06% |
CDXS | 250.7M | 138.6M | -19.03% | -80.42% | -7.46 | 1.81 | 32.30% | -57.86% |
HBIO | 126.7M | 113.3M | 13.22% | -43.77% | -13.31 | 1.12 | -4.68% | -3204.17% |
PSNL | 125.6M | 65.0M | -11.53% | -66.71% | -1.11 | 1.93 | -23.92% | -73.73% |
CSBR | 56.3M | 54.1M | -9.78% | -51.18% | 521 | 1.04 | 21.80% | -72.38% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -6.3% | 128,304,000 | 136,970,000 | 139,546,000 | 134,689,000 | 130,513,000 |
Cost Of Revenue | 3.9% | 79,269,000 | 76,309,000 | 77,068,000 | 74,651,000 | 71,653,000 |
Gross Profit | -19.2% | 49,035,000 | 60,661,000 | 62,478,000 | 60,038,000 | 58,860,000 |
Operating Expenses | 3.1% | 356,231,000 | 345,449,000 | 347,122,000 | 314,286,000 | 269,295,000 |
S&GA Expenses | 5.0% | 160,854,000 | 153,171,000 | 147,982,000 | 137,790,000 | 124,124,000 |
R&D Expenses | 0.0% | 193,000,000 | 192,953,000 | 173,369,000 | 145,287,000 | 112,899,000 |
EBITDA | -8.8% | -290,078,000 | -266,535,000 | -252,572,000 | - | - |
EBITDA Margin | -16.2% | -2.26 | -1.95 | -1.88 | - | - |
Earnings Before Taxes | -8.3% | -314,248,000 | -290,250,000 | -274,872,000 | - | - |
EBT Margin | -15.6% | -2.45 | -2.12 | -2.04 | - | - |
Interest Expenses | 1.2% | 14,690,000 | 14,521,000 | 14,530,000 | 14,438,000 | 12,530,000 |
Net Income | -5.0% | -314,248,000 | -299,193,000 | -205,680,000 | -175,287,000 | -181,223,000 |
Net Income Margin | -12.1% | -2.45 | -2.18 | -1.47 | -1.30 | - |
Free Cahsflow | -12.4% | -279,961,000 | -249,041,000 | -223,574,000 | -176,273,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -2.9% | 1,767 | 1,819 | 1,876 | 1,937 | 2,007 |
Current Assets | -6.8% | 852 | 914 | 970 | 1,029 | 1,101 |
Cash Equivalents | 6.8% | 325 | 304 | 310 | 429 | 461 |
Inventory | 15.8% | 50.00 | 43.00 | 36.00 | 30.00 | 25.00 |
Net PPE | 6.2% | 42.00 | 39.00 | 38.00 | 36.00 | 33.00 |
Goodwill | 0% | 410 | 410 | 410 | 410 | 410 |
Liabilities | 1.0% | 1,204 | 1,192 | 1,194 | 1,202 | 1,216 |
Current Liabilities | 222.5% | 263 | 82.00 | 84.00 | 61.00 | 72.00 |
Shareholder's Equity | -10.2% | 563 | 627 | 682 | 735 | 791 |
Retained Earnings | -5.8% | -1,532 | -1,447 | -1,370 | -1,299 | -1,218 |
Additional Paid-In Capital | 0.9% | 2,100 | 2,081 | 2,058 | 2,038 | 2,010 |
Shares Outstanding | 0.3% | 227 | 226 | 225 | 224 | 221 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -12.3% | -263 | -234 | -211 | -167 | -111 |
Share Based Compensation | -1.2% | 79.00 | 80.00 | 89.00 | 86.00 | 73.00 |
Cashflow From Investing | 14.4% | 116 | 101 | -244 | -644 | -678 |
Cashflow From Financing | -5.0% | 10.00 | 10.00 | 307 | 309 | 1,170 |
100%
90%
72.3%
Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.
14.1%
2.3%
33.7%
41.6%
FIve years rolling returns for Pacific Biosciences of California.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | unchanged | - | 279,915 | 964,087 | 0.01% |
2023-03-17 | American Portfolios Advisors | reduced | -1.48 | 38,948 | 171,486 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.04 | 54,862 | 187,862 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 107 | 6,000 | 8,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 205,282 | 708,282 | -% |
2023-02-28 | Orin Green Financial, LLC | unchanged | - | 28,160 | 98,160 | 0.06% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -99.45 | -1,046,880 | 8,123 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -2,300,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 650 | 650 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -0.27 | 9,458,000 | 32,822,000 | 0.04% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital international investors | 2.7% | 6,099,681 | SC 13G/A | |
Feb 13, 2023 | madrone capital partners, llc | 7.3% | 16,415,933 | SC 13G/A | |
Feb 10, 2023 | nikko asset management americas, inc. | 6.26% | 14,166,193 | SC 13G/A | |
Feb 10, 2023 | ark investment management llc | 11.36% | 25,691,681 | SC 13G/A | |
Feb 10, 2023 | jackson square partners, llc | 6.64% | 15,005,177 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.97% | 20,279,035 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.2% | 18,534,459 | SC 13G/A | |
Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 6.26% | 14,166,193 | SC 13G/A | |
Jun 01, 2022 | madrone capital partners, llc | 6.0% | 13,415,933 | SC 13G | |
Feb 14, 2022 | nikko asset management americas, inc. | 5.40% | 11,915,025 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.47 -94.96% | 0.50 -94.64% | 0.57 -93.88% | 0.69 -92.60% | 0.86 -90.77% |
Current Inflation | 0.47 -94.96% | 0.50 -94.64% | 0.56 -93.99% | 0.66 -92.92% | 0.81 -91.31% |
Very High Inflation | 0.47 -94.96% | 0.49 -94.74% | 0.54 -94.21% | 0.63 -93.24% | 0.75 -91.95% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 27, 2023 | PRE 14A | PRE 14A | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 10-K | Annual Report | |
Feb 28, 2023 | S-8 | Employee Benefits Plan | |
Feb 22, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-15 | Ericson William W. | sold | -67,114 | 8.9 | -7,541 | - |
2023-03-15 | Ericson William W. | acquired | 63,500 | 2.54 | 25,000 | - |
2023-03-03 | Kim Susan G. | sold | -47,892 | 9.493 | -5,045 | see remarks |
2023-03-03 | Farmer Michele | sold | -29,931 | 9.493 | -3,153 | see remarks |
2023-03-03 | Van Oene Mark | sold | -59,502 | 9.493 | -6,268 | see remarks |
2023-03-03 | HENRY CHRISTIAN O | sold | -130,709 | 9.493 | -13,769 | see remarks |
2023-03-02 | HENRY CHRISTIAN O | acquired | - | - | 594,687 | see remarks |
2023-03-02 | Van Oene Mark | acquired | - | - | 328,500 | see remarks |
2023-03-02 | Kim Susan G. | acquired | - | - | 164,200 | see remarks |
2023-03-02 | Eidel Jeff | acquired | - | - | 164,200 | see remarks |
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) shares in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 128,304,000 | $ 130,513,000 | $ 78,893,000 |
Cost of Revenue: | |||
Amortization of intangible assets | 733,000 | 306,000 | |
Loss on purchase commitment | 3,705,000 | ||
Total cost of revenue | 79,269,000 | 71,653,000 | 46,327,000 |
Gross profit | 49,035,000 | 58,860,000 | 32,566,000 |
Operating Expense: | |||
Research and development | 193,000,000 | 112,899,000 | 64,152,000 |
Sales, general and administrative | 160,854,000 | 124,124,000 | 72,799,000 |
Merger-related expenses | 31,129,000 | ||
Change in fair value of contingent consideration | 2,377,000 | 1,143,000 | |
Total operating expense | 356,231,000 | 269,295,000 | 136,951,000 |
Operating loss | (307,196,000) | (210,435,000) | (104,385,000) |
Gain from Reverse Termination Fee from Illumina | 98,000,000 | ||
(Loss)/Gain from Continuation Advances from Illumina | (52,000,000) | 34,000,000 | |
Interest expense | (14,690,000) | (12,530,000) | (267,000) |
Other income, net | 7,638,000 | 93,000 | 2,055,000 |
(Loss) income before benefit from income taxes | (314,248,000) | (274,872,000) | 29,403,000 |
Benefit from income taxes | (93,649,000) | ||
Net (loss) income | (314,248,000) | (181,223,000) | 29,403,000 |
Other comprehensive (loss) income: | |||
Unrealized (loss) gain on investments | (3,678,000) | (1,172,000) | 80,000 |
Comprehensive (loss) income: | $ (317,926,000) | $ (182,395,000) | $ 29,483,000 |
Net (loss) income per share: | |||
Basic | $ (1.40) | $ (0.89) | $ 0.18 |
Diluted | $ (1.40) | $ (0.89) | $ 0.17 |
Weighted average shares outstanding used in calculating net (loss) income per share: | |||
Basic | 224,550 | 204,136 | 165,187 |
Diluted | 224,550 | 204,136 | 174,970 |
Product [Member] | |||
Revenue: | |||
Total revenue | $ 108,699,000 | $ 113,505,000 | $ 65,424,000 |
Cost of Revenue: | |||
Cost of product revenue | 60,932,000 | 56,358,000 | 35,424,000 |
Service and Other [Member] | |||
Revenue: | |||
Total revenue | 19,605,000 | 17,008,000 | 13,469,000 |
Cost of Revenue: | |||
Cost of service and other revenue | $ 13,899,000 | $ 14,989,000 | $ 10,903,000 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 325,089 | $ 460,725 |
Investments | 447,229 | 583,675 |
Accounts receivable, net | 18,786 | 24,241 |
Inventory, net | 50,381 | 24,599 |
Prepaid expenses and other current assets | 10,289 | 7,394 |
Short-term restricted cash | 300 | 500 |
Total current assets | 852,074 | 1,101,134 |
Property and equipment, net | 41,580 | 32,504 |
Operating lease right-of-use assets, net | 39,763 | 46,617 |
Long-term restricted cash | 2,922 | 4,592 |
Intangible assets, net | 410,245 | 410,979 |
Goodwill | 409,974 | 409,974 |
Other long-term assets | 10,528 | 1,170 |
Total assets | 1,767,086 | 2,006,970 |
Current liabilities | ||
Accounts payable | 12,028 | 11,002 |
Accrued expenses | 32,596 | 36,261 |
Deferred revenue, current | 30,498 | 10,977 |
Operating lease liabilities, current | 8,886 | 7,710 |
Other liabilities, current | 7,233 | 5,759 |
Contingent consideration liability, current | 172,094 | |
Total current liabilities | 263,335 | 71,709 |
Deferred revenue, non-current | 1,794 | 25,049 |
Contingent consideration liability, non-current | 169,717 | |
Operating lease liabilities, non-current | 41,070 | 49,970 |
Convertible senior notes, net, non-current | 896,683 | 896,067 |
Other liabilities, non-current | 1,300 | 3,471 |
Total liabilities | 1,204,182 | 1,215,983 |
Commitments and contingencies | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding | ||
Common stock, $0.001 par value: Authorized 1,000,000 shares; issued and outstanding 226,505 and 220,978 shares at December 31, 2022 and December 31, 2021, respectively | 227 | 221 |
Additional paid-in capital | 2,099,782 | 2,009,945 |
Accumulated other comprehensive loss | (4,765) | (1,087) |
Accumulated deficit | (1,532,340) | (1,218,092) |
Total stockholders' equity | 562,904 | 790,987 |
Total liabilities and stockholders' equity | $ 1,767,086 | $ 2,006,970 |